Advanced Search

 

Study ID Status Title Patient Level Data
SUM30028 Completed A double-blind, placebo-controlled, parallel group study to evaluate two dose levels (10mg and 20mg) of intranasal sumatriptan in the acute treatment of migraine attack.
SUM30029 Completed An open design study to evaluate the efficacy and tolerability of sumatriptan nasal spray (20mg + optional 20mg dose for headache recurrence) in the acute treatment of migraine during a 12 month period.
SUM30030 Completed A randomised, double-blind, double-dummy, cross-over study to compare the efficacy and safety of sumatriptan nasal spray (20mg) with dihydroergotamine (DHE) nasal spray (1mg plus optional 1mg) in the acute treatment of migraine.
SUM30031 Completed A Randomized Double-Blind, Placebo-Controlled, Crossover Protocol to Evaluate the Safety and Efficacy of 12.5mg and 25mg Sumatriptan Suppository in the Treatment of Multiple Migraine Attacks.
SUM30032 Completed A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Sumatriptan Suppositories in the Acute Treatment of Three Migraine Attacks.
SUM30034 Completed A double-blind, placebo-controlled study to compare the efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg film-coated tablets) in the acute treatment of migraine with an optional second dose to treat recurrence.
SUM30035 Completed A double-blind, crossover study to assess patient preference, efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg film-coated tablets) in the acute treatment of migraine.
SUM30037 Completed A double-blind placebo controlled study to assess the efficacy/safety of oral sumatriptan (50mg film coated tablet) in the acute treatment of migraine with an optional second dose to treat recurrence.
SUM30042 Completed A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Efficacy, Safety and Tolerability of Sumatriptan Nasal Spray (10mg or 20mg) in the Treatment of Acute Migraine in Patients Aged 12-17.
SUM30045 Completed A Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate Two Dose Levels (5mg And 20mg) Of Sumatriptan Nasal Spray In The Acute Treatment Of A Single Migraine Attack In Adolescent Migraineurs (12-17 Years Of Age) Study Listed on ClinicalStudyDataRequest.com
SUM30046 Completed A randomised, double-blind, single-attack, placebo-controlled, parallel group evaluation of the efficacy and tolerability of sumatriptan Fast Disintegrating Tablets (FDT) 50 mg and 100 mg versus placebo during the mild pain phase of a migraine attack. Study Listed on ClinicalStudyDataRequest.com
SUM30047 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine Study Listed on ClinicalStudyDataRequest.com
SUM30053 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine (EU study). Study Listed on ClinicalStudyDataRequest.com
SUM40019 Completed A double blind, placebo-controlled, two-way cross-over study investigating the efficacy of Sumatriptan nasal spray in Children’s Migraine.
SUM40022 Completed A randomised, controlled, partly crossover study of clinical efficacy, economic impact and quality of life of sumatriptan nasal spray (20mg) compared to patient’s customary treatment in acute migraine attacks in a workplace setting.
SUM40026 Completed Double-blind, randomised, placebo-controlled, four period cross-over comparative study on CNS effects of two oral doses separated by 2 hours of rizatriptan (2x10mg), sumatriptan (2x50mg), an active comparator temazepam (placebo followed by 20mg two hours later) and placebo in healthy female subj ...
SUM40029 Completed Pharmacokinetics and user acceptability of Intraject sumatriptan vs GW auto-injector (Subject, Self or Statdose) in migraine patients outside of an attack.
SUM40031 Completed A randomised double-blind, double-dummy, single-attack, parallel group study to compare the speed of onset of sumatriptan nasal spray (20mg) with rizatriptan wafer (10mg) in the acute treatment of migraine.
SUM40036 Completed A study of the pharmacokinetics and bioequivalence of the Japanese and GWUK market formulations of sumatriptan succinate performed in Japanese and Caucasian populations.
SUM40056 Completed An open-label study to rechallenge patients who had previously experienced an adverse event involving discomfort or pain in the chest or throat following sumatriptan administration (SC or oral). Rechallenge during a migraine attack with subcutaneous sumatriptan 6mg.
SUM40058 Completed A double-blind, randomised, placebo controlled, crossover study to assess return of headache in patients treated with 6mg subcutaneous sumatriptan early or late in a migraine attack; with optional open-label doses to assess pattern of use of sumatriptan over the subsequent 72 hour period.
SUM40083 Completed A double-blind, placebo-controlled, parallel group study to evaluate the efficacy of subcutaneous GR43175C (6mg & optional 6mg) in the acute treatment of menstrual migraine – with optional open follow-up treatment: Phase I.
SUM40083_1 Completed A double-blind, placebo-controlled, parallel group study to evaluate the efficacy of subcutaneous GR43175C (6mg & optional 6mg) in the acute treatment of menstrual migraine – with optional open follow-up treatment. Phase II.
SUM40090 Completed The use of oral sumatriptan on compassionate grounds for the acute treatment of migraine in adolescent patients (ages 12 to 17).
SUM40126 Completed An open design, multiple treatment study to evaluate subcutaneous sumatriptan (6mg) in the acute treatment of cluster headache attacks during a 3-month period.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.